Ladenburg adjusted the firm’s price target on NeuroOne Medical (NMTC) to $8 from $1.60 and keeps a Buy rating on the shares. It cites the one-for-six reverse stock split for the change.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMTC:
- NeuroOne Earnings Call Balances Growth With Cash Strain
- NeuroOne Regains Nasdaq Compliance After Bid Price Recovery
- NeuroOne Appoints New CFO Amid Planned Leadership Transition
- Analyst Reaffirms Buy on NeuroOne After Reverse Split, Adjusts Valuation and Lowers Price Target to $8
- Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/23/26?